综述:肠道微生物组作为慢性肝病发病机制与治疗中的治疗靶点
该综述通过PubMed检索微生物组、肝脏、肝硬化、非酒精性脂肪性肝病、脂肪性肝炎、酒精及原发性硬化性胆管炎等文献,描述慢性肝病中肠道微生物组的变化,并评估操纵微生物组对肝脏的影响,认为通过饮食、益生菌或粪菌移植促进「健康」细菌生长可能改善菌群失调并改变预后。
要点
- 多种慢性肝病可见细菌多样性降低、酒精敏感性和肠道菌群失调。
- 肠道共生菌扰动可致免疫系统启动不足,易患免疫介导疾病。
- 代谢综合征动物粪便转移可诱导健康同类动物脂肪变性。
核心结论
- 通过饮食、益生菌或粪菌移植操纵肠道微生物组以促进「健康」细菌生长,可能改善菌群失调并改变预后。
研究设计与样本
- 综述:通过PubMed检索包含「microbiome」「liver」「cirrhosis」「non-alcoholic fatty liver disease」「steatohepatitis」「alcohol」「primary sclerosing cholangitis」等术语的文献,并从文章参考文献和ClinicalTrials.gov网站选取相关文章。
主要发现
- 非酒精性脂肪性肝病、酒精相关肝病和原发性硬化性胆管炎等多种慢性肝病中可见细菌多样性降低、酒精敏感性和肠道菌群失调。
- 肠道共生菌扰动可能导致免疫系统启动不足,易患免疫介导疾病。
- 来自代谢综合征动物的粪便转移可诱导健康同类动物脂肪变性。
- 肝硬化患者出现菌群失调、小肠细菌过度生长和肠壁通透性增加,允许细菌移位和内毒素摄取,诱导肝脏和全身炎症。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mortality from chronic liver disease is rising exponentially. The liver is intimately linked to the gut via the portal vein, and exposure to gut microbiota and their metabolites translocating across the gut lumen may impact upon both the healthy and diseased liver. Modulation of gut microbiota could prove to be a potential therapeutic target. AIM: To characterise the changes in the gut microbiome that occur in chronic liver disease and to assess the impact of manipulation of the microbiome on the liver. METHODS: We conducted a PubMed search using search terms including 'microbiome', 'liver' and 'cirrhosis' as well as 'non-alcoholic fatty liver disease', 'steatohepatitis', 'alcohol' and 'primary sclerosing cholangitis'. Relevant articles were also selected from references of articles and review of the ClinicalTrials.gov website. RESULTS: Reduced bacterial diversity, alcohol sensitivity and the development of gut dysbiosis are seen in several chronic liver diseases, including non-alcoholic fatty liver disease, alcohol-related liver disease and primary sclerosing cholangitis. Perturbations in gut commensals could lead to deficient priming of the immune system predisposing the development of immune-mediated diseases. Furthermore, transfer of stool from an animal with the metabolic syndrome may induce steatosis in a healthy counterpart. Patients with cirrhosis develop dysbiosis, small bowel bacterial overgrowth and increased gut wall permeability, allowing bacterial translocation and uptake of endotoxin inducing hepatic and systemic inflammation. CONCLUSIONS: Manipulation of the gut microbiota with diet, probiotics or faecal microbiota transplantation to promote the growth of "healthy" bacteria may ameliorate the dysbiosis and alter prognosis.
引用
- Woodhouse CA, Patel VC, Singanayagam A, et al. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease. Aliment Pharmacol Ther. 2017. PMID: 29083037. doi:10.1111/apt.14397
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。